Preclinical Phase

PharmaCyte Biotech Inc (NASDAQ: PMCB) updated its activities to lift the FDA's clinical hold on PharmaCyte's treatment for locally advanced, inoperable pancreatic cancer (LAPC).  After submitting an initial Investigational New Drug Application (IND), the FDA requested...

Decibel Therapeutics Inc (NASDAQ: DBTX) announced the presentation of preclinical data on DB-OTO, its lead gene therapy product candidate. DB-OTO is a dual-vector adeno-associated candidate designed to restore hearing to individuals with profound, congenital hearing loss caused by mutations...

Immunoprecise Antibodies Ltd (NASDAQ: IPA) has released preclinical data for the PolyTope TATX-03 COVID-19 antibody cocktail. The data demonstrated robust neutralizing potency of the antibody cocktail towards the omicron variant (B.1.1.529) in in vitro pseudovirus assays....

IDEAYA Biosciences Inc (NASDAQ: IDYA) has initiated IND-enabling studies for IDE161, a potential first-in-class PARG inhibitor development candidate.  IDEAYA is targeting an IND submission for IDE161 in Q4 Of 2022. The company plans to evaluate IDE161 in patients having tumors with...

Alterity Therapeutics's (NASDAQ: ATHE) data in an animal model of Multiple System Atrophy (MSA) were published in the Journal of Parkinson's Disease.  The publication describes a study evaluating the efficacy of ATH434 in genetically altered mice that develop manifestations of...

Immix Biopharma Inc's (NASDAQ: IMMX) IMX-110 + anti-PD-1 produced 63-day median survival in a genetic pancreatic cancer mouse model, in which mice develop their own pancreatic cancer and have an intact immune system. Historically, 42-days is the median survival produced by a 4-drug...

HCW Biologics Inc (NASDAQ: HCWB) has announced the publication of a scientific paper in Molecular Therapy highlighting preclinical data of its lead program, HCW9218. The preclinical data demonstrated that HCW9218 enhanced the anti-tumor efficacy of chemotherapy drugs and diminished their...

Can-Fite BioPharma Ltd (NYSE: CANF) announced preclinical studies with skin cells, modeling psoriasis in humans, showing that Piclidenoson destroys pathological skin cells.  Piclidenoson is the company's lead drug candidate for the treatment of psoriasis. The company's...

Heat Biologics Inc (NASDAQ: HTBX) announced promising preclinical data regarding PTX-35. The data has been accepted for publication in the American Journal of Transplantation. A single dose of the preclinical version of PTX-35 (mPTX-35) expanded regulatory T cells (Tregs) and...

Immix Biopharma Inc (NASDAQ: IMMX) announced preclinical data of its lead program, IMX-110. The data showed that IMX-110 produced a 50% response rate in first-line-therapy-resistant cancer - soft tissue sarcoma (STS) mouse study, surpassing the STS standard of care doxorubicin...

Revelation Biosciences Inc (NASDAQ: REVB) says that it observed a significant decrease in viral load with the prophylactic treatment of REVTx-99 in models of COVID-19 infection. What Happened: REVTx-99 was assessed for prophylactic antiviral activity against delta variant infection in three...

In preclinical studies, Lixte Biotechnology Holdings Inc's (NASDAQ: LIXT) lead clinical compound, LB-100, increased the responsiveness of diverse cancers to immunotherapy.  The data reported that treatment with LB-100 is associated with new antigen production, tumor...

Hoth Therapeutics Inc (NASDAQ: HOTH) announced proof-of-concept data generated using an Alzheimer's disease mouse model, supporting the therapeutic potential of HT-ALZ.  HT-ALZ is in development under the 505(b)(2) regulatory pathway for the treatment of dementia-related to...

Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) has announced an exclusive option agreement and research collaboration with Kansas State University (K-State) to develop zinc nanoparticle (ZNP) mRNA vaccines. The ZNP technology replaces the lipid-nanoparticle (LNP) technology in...

BiondVax Pharmaceuticals Ltd (NASDAQ: BVXV) has entered into agreements with the Max Planck Society and the University Medical Center Göttingen in Germany.  The parties intend to enter into a 5-year strategic research collaboration, including an option for BiondVax to...